Narita, Ichiei
Tsubakihara, Yoshiharu
Takahashi, Naoko
Ebata, Toshiya
Uchiyama, Takuma
Marumo, Masaya
Okamura, Shota
Gejyo, Fumitake
Fukaya, Yasuo
Yajima, Takahiro
Hamamoto, Yukihiro
Hagiwara, Noriyasu
Itami, Noritomo
Komeda, Masami
Kim, Jong Il
Hattori, Hideaki
Ishii, Sakae
Imanishi, Masahito
Funakoshi, Satoshi
Ohsawa, Isao
Degawa, Noriyuki
Endo, Toko
Toyoda, Mariko
Akamatsu, Yorihiro
Ito, Sadayoshi
Sato, Takashi
Udagawa, Takashi
Otsuka, Masakazu
Sato, Masatsugu
Oguchi, Tomomasa
Yano, Shintaro
Saka, Yosuke
Shimizu, Hiroyuki
Ogura, Haruyuki
Kagawa, Toru
Senga, Yutaka
Kawaguchi, Yuji
Fujisaki, Kiichiro
Shimizu, Hideaki
Aizawa, Nobuyuki
Shigehara, Tetsuya
Nishio, Toshiki
Matsukawa, Hideki
Masakane, Ikuto
Kikuchi, Hiroshi
Okada, Noriyuki
Obayashi, Hiroaki
Yoshitomi, Ryota
Oka, Harumichi
Ito, Kyoko
Kimura, Naoaki
Ando, Shigeki
Shibata, Toshiro
Shimada, Hisaki
Yanase, Masahiro
Isono, Motohide
Shibuya, Kouji
Sasagawa, Isoji
Sugiyama, Satoshi
Ogawa, Hiroshi
Motonishi, Shuta
Hiraiwa, Nozomu
Taniguchi, Masatomo
Yoshida, Yuichi
Kurosawa, Akira
Oguchi, Kenichi
Omata, Momoyo
Oura, Masaharu
Kinuno, Hiroyuki
Ohishi, Akira
Watanabe, Makoto
Toyoyama, Takayuki
Fujita, Yoshiro
Hirayama, Kouichi
Maruyama, Yasuyuki
Obunai, Suguru
Yamagishi, Takashi
Takaeda, Chikako
Hayashi, Daiki
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term efficacy and safety of difelikefalin in moderate-to-severe pruritus in Japanese hemodialysis patients: a 52-week open-label extension period of a phase 3 trial
https://doi.org/10.1186/s41100-024-00557-9
Funding for this research was provided by:
Kissei
Article History
Received: 18 March 2024
Accepted: 27 June 2024
First Online: 19 July 2024
Declarations
:
: The study protocol, informed consent form, and other relevant study documentations were approved by the institutional review board. All patients gave written informed consent before initiation of any study-specific procedures.
: Not applicable.
: N.T. and T.E. received consultant fees from Kissei Pharmaceutical. T.U., M.M., and S.O. are employees of Kissei Pharmaceutical. The other authors declare that they have no competing interests.